



Prothena Corporation plc  
Investor Relations Department  
331 Oyster Point Blvd  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: PRTA

Last Trade:	33.06
Trade Time:	4:00 PM ET Feb 20, 2018
Change:	-0.14  (-0.422%)
Day Range	32.66 - 33.92
52-Week Range	27.19 - 70.00
Volume	364,905

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Feb 14, 2018*

[Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update](#)

*Feb 7, 2018*

[Prothena to Participate in the Leerink Partners 7th Annual Global Healthcare Conference](#)

*Feb 2, 2018*

[Prothena Announces Departure of Chief Medical Officer](#)

*Feb 1, 2018*

[Prothena to Report Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 14](#)

*Jan 3, 2018*

[Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference](#)

## Financials [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

*Feb 27, 2017*

[Annual Report \(10-K\)](#)

*Mar 31, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 7, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 9, 2017*

[Quarterly Report \(10-Q\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)